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A B S T R A C T
Hemophilia A is an inherited bleeding disorder characterized by factor VIII deficiency. The basis for insufficient
hemostasis lies within inadequate amplification of factor Xa production with the undersupplied factor VIII. We report on
a young patient with critical aortic stenosis bearing all the clinical stigmata of severe hemophilia, in whom aortic valve
replacement was performed with a tissue valve in order to avoid the need for long term anticoagulation.
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Introduction
The substantial improvements in the management of
patients with hemophilia have resulted in significant
prolongation of their life expectancy1. While the preva-
lence of cardiac pathology in patients with hemophilia
may be lower than in the healthy population of similar
demographic characteristics, it is likely to be influenced
by the mentioned aging of the hemophiliac population1.
This fact brings into focus the importance of recognizing
the risks associated with performing major cardiac surgi-
cal procedures in patients with inherited bleeding disor-
ders. The complex coagulation disturbance provoked by
cardiopulmonary bypass further adds to the patient’s al-
ready defective hemostatic potential2. Prothrombin com-
plex concentrates, activated prothrombin concentrates
as well as recombinant factor VIIa have all been used in
the prevention and treatment of bleeding associated with
major surgical procedures in hemophiliacs3.
Case Report
We present a 47-year-old man with a severe form of
hemophilia A without inhibitors, who was referred for
surgical management of his symptomatic aortic stenosis.
He had already undergone shoulder, hip and knee re-
placements due to joint complications of his underlying
illness.
He had echocardiographic evidence of severe calcific
aortic stenosis, with a mean gradient of 58 mmHg in the
setting of preserved left ventricular function. He com-
plained of angina and progressive dyspnea on exertion.
He underwent coronary angiography which showed mild
nonobstructive coronary artery disease. Of note, he was
HIV antibody, hepatitis B surface antigen and hepatitis C
antibody negative. While there is little doubt that a pa-
tient of the same age group with a competent coagulation
mechanism could have been offered a mechanical valve
prosthesis, the choice in our patient was less simple. Fol-
lowing a detailed discussion with the patient which en-
compassed all the limitations of the various options for
aortic valve replacement (AVR), we opted to use a third
generation tissue prosthesis for his scheduled AVR. The
patient’s preoperative factor VIII level was 0.005 IU/dL.
He received a 2500 U bolus (B1) of factor VIII the night
before surgery. A repeat 4500 U dose (B2) was given 1
hour prior to the skin incision followed by a continuous
infusion of 270 IU/hr, which enhanced the factor VIII ac-
tivity to 107% (Figure 1). The operative strategy also in-
cluded administration of the antifibrinolytic aprotinin
and use of a cell-saver device, while exceptional emphasis
on a meticulous surgical technique was insisted upon.
The patient was anticoagulated for cardiopulmonary by-
pass (CPB) with a 3 mg/kg bolus dose of systemic heparin
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to achieve an activated clotting time in excess of 480 sec-
onds. Prior to institution of CPB another 5000 U bolus
dose (B3) of the antihemophilic factor was given, while
the continuous infusion was increased to 370 IU/hr4. The
operation was performed in the standard fashion which
included a median sternotomy approach and use of nor-
mothermic cardiopulmonary bypass. Following aortic cross
clamping an oblique aortotomy was made and cold blood
cardioplegia delivered directly into the coronary ostia.
On inspection, the aortic valve was found to be tricuspid
with extensive leaflet calcifications extending into the
valve annulus. Following the excision of all disease leaf-
lets, a thorough debridement and decalcification ensued.
The aortic valve annulus was then calibrated and a 27
mmMedtronic Mosaic tissue valve (Medtronic, Minneap-
olis, USA) was inserted. The patient was weaned off car-
diopulmonary bypass without inotropic support, and the
competence of the prosthesis was demonstrated by trans-
esophageal echocardiography. The factor VIII activity
was boosted again at the conclusion of the operation, in
synchrony to heparin’s reversal with protamine.
The patient had an uneventful postoperative course.
While the combination of the coagulation defect trig-
gered by cardiopulmonary bypass in addition to the fac-
tor VIII deficiency made the prospect of increased peri-
operative blood loss a likely possibility, the chest tube
output for the first 24 hours remained below 350 mL.
The micromanagement of the continuous factor VIII in-
fusion was done in collaboration with a hematologist and
was continued until postoperative day twelve, when it
was substituted for intermittent bolus dosing with the
goal of maintaining the factor VIII activity above 40%.
Discussion
The life expectancy of patients with hemophilia is cur-
rently estimated to be between 60 and 70 years. It is,
therefore, foreseeable that the problem of approaching a
patient with hemophilia requiring a valve replacement
might begin to occur with greater frequency. The incom-
petent hemostatic mechanism in hemophiliacs may con-
fer a protective effect in terms of retarding the process of
thrombosis superimposed upon atherosclerotic lesions,
but no apparent link to aortic valve disease has thus far
been identified. The paucity of published data falls short
in providing unequivocal guidelines for the choice of a
valve prosthesis in this specific clinical scenario1,5. Taking
into consideration that our patient’s inherited bleeding
disorder had already burdened him with serious bleed-
ing-related complications, we were more inclined to use a
biological prosthesis in order to avoid the need for long
term warfarin.
The complex coagulation disorder known to be precip-
itated by cardiopulmonary bypass coupled with the un-
derlying factor VIII deficiency warranted a judicious
multidisciplinary approach. Our intraoperative anticoa-
gulation strategy did not differ from our routine manage-
ment, and included heparin and its reversal with pro-
tamine. Whether administration of factor VIII during
cardiopulmonary bypass is necessary or not in order to
neutralize the hemodilutive effect of CPB remains a
point of controversy. Our tactic was to continue factor
VIII continuously and supplement it with intermittent
boluses prior to the commencement of CPB and immedi-
ately upon its discontinuation. The continuous infusion
of factor VIII was maintained until postoperative day
twelve, which coincided with the removal of the last of
the patient’s stitches. The available data in the literature
discourages the use of aspirin in the hemophiliac popula-
tion, and neither aspirin nor warfarin was given to our
patient at any time1.
The decision to operate on the presented patient was
not made hastily. One should be reluctant to operate on a
patient with asymptomatic aortic stenosis and a severe
comorbidity based on echocardiographic appearance alone.
However, our patient presented with both echocardio-
graphic and clinical evidence of severe aortic stenosis. It
was his worsening clinical condition that prompted us to
proceed with surgery. We believed that the natural pro-
gression of his cardiac pathology outweighed the sub-
stantial risk of surgery.
The optimal choice of a valve prosthesis is undoubt-
edly of paramount importance, and we believe that a pa-
tient specific approach is warranted. Avoiding the perils
of lifelong anticoagulation with warfarin in a patient
with severe hemophilia comes at a cost of reduced pros-
thetic valve durability. With reoperative procedures be-
coming more prevalent in the contemporary cardiac sur-
gical practice, however, we believe that future re-do valve
replacement can be offered with low mortality.
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Fig. 1. Correlation of the factor VIII level with the continuous
factor VIII infusion complemented with intermittent boluses (B1–3)
in the immediate perioperative period.
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ZAMJENA AORTALNE VALVULE KOD BOLESNIKA SA TE[KOM HEMOFILIJOM
S A @ E T A K
Hemofilija A je nasljedni poreme}aj koagulacije koji je karakteriziran nedostatkom faktora VIII. U podlozi manjka-
vog hemostatskog potencijala je neadekvatna amplifikacija faktora Xa sa faktorom VIII. Ovaj prikaz slu~aja fokusira se
na mladog bolesnika sa kriti~nom stenozom aortalne valvule koji boluje od te{kog oblika hemofilije A. Strategija kirur-
{kog lije~enja bazirala se na zamjeni aortalne valvule sa tkivnom protezom kako bi se izbjegla dugoro~na antikoagu-
lacija
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